Compare 8x8 Inc (EGHT) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Regeneron Pharmaceuticals Inc — how do they compare? 8x8 Inc trades at $2 (market cap $309.09M), while Regeneron Pharmaceuticals Inc trades at $796.95 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 265.5× 8x8 Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals.
| EGHT | REGN | |
|---|---|---|
Market Cap | $309.09M | $82.06B |
Sector | Technology | Health |
52-Week High | $2.76 | $812.27 |
52-Week Low | $1.59 | $555.51 |
Enterprise Value | $576.02M | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.01, down 10.27% today, with a bullish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights AI platform expansion and partner program enhancements driving growth.
The outlook appears constructive with analyst consensus target of $3.13 representing 56% upside potential. Key risks include high debt levels and negative retained earnings, while catalysts include continued AI adoption and revenue growth acceleration toward profitability.
Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.
Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
